Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.
复制标题

DOI:
10.1038/s41541-022-00477-x
复制
发表时间:
2022-05-18
期刊:
影响因子:
9.2
通讯作者:
Barouch, Dan H.
Barouch, Dan H.
中科院分区:
医学1区
文献类型:
--
作者:
Ventura, John D.;Nkolola, Joseph P.;Chandrashekar, Abishek;Borducchi, Erica N.;Liu, Jinyan;Mercado, Noe B.;Hope, David L.;Giffin, Victoria M.;McMahan, Katherine;Geleziunas, Romas;Murry, Jeffrey P.;Yang, Yunling;Lewis, Mark G.;Pau, Maria G.;Wegmann, Frank;Schuitemaker, Hanneke;Fray, Emily J.;Kumar, Mithra R.;Siliciano, Janet D.;Siliciano, Robert F.;Robb, Merlin L.;Michael, Nelson L.;Barouch, Dan H.

文献摘要

参考文献

相似文献

开发一种干预措施,在停止抗逆转录病毒治疗(ART)后,导致病毒学控制是HIV-1治愈研究的主要目标。在这项研究中,我们研究了由腺病毒血清型26(Ad 26)和改良的安卡拉牛痘(MVA)组成的疫苗(含或不含SIV包膜(Env)gp 140蛋白)与明矾佐剂联合TLR 7激动剂vesatolimod(GS-9620)在36只ART抑制的SIVmac 251感染恒河猴中的治疗效果。Ad 26/MVA治疗性疫苗接种导致强烈的体液和细胞免疫应答,并且Env蛋白加强增加抗体应答。ART停药后,在每个疫苗组的5/12只动物中观察到病毒学控制,而假手术对照组为0/12只动物。这些数据证明了用vesatolimod进行的Ad 26/MVA疫苗接种的治疗功效,但没有添加Env蛋白加强的明确的额外益处。SIV特异性细胞免疫应答与病毒学控制相关。我们的研究结果显示,在SIV感染的恒河猴中,ART停止后治疗性疫苗接种的部分疗效。
Developing an intervention that results in virologic control following discontinuation of antiretroviral therapy (ART) is a major objective of HIV-1 cure research. In this study, we investigated the therapeutic efficacy of a vaccine consisting of adenovirus serotype 26 (Ad26) and modified vaccinia Ankara (MVA) with or without an SIV Envelope (Env) gp140 protein with alum adjuvant in combination with the TLR7 agonist vesatolimod (GS-9620) in 36 ART-suppressed, SIVmac251-infected rhesus macaques. Ad26/MVA therapeutic vaccination led to robust humoral and cellular immune responses, and the Env protein boost increased antibody responses. Following discontinuation of ART, virologic control was observed in 5/12 animals in each vaccine group, compared with 0/12 animals in the sham control group. These data demonstrate therapeutic efficacy of Ad26/MVA vaccination with vesatolimod but no clear additional benefit of adding an Env protein boost. SIV-specific cellular immune responses correlated with virologic control. Our findings show partial efficacy of therapeutic vaccination following ART discontinuation in SIV-infected rhesus macaques.
DOI: 10.1371/journal.ppat.1003658
发表时间: 2013
期刊: PLoS pathogens
影响因子: 6.7
作者:
Fraietta JA;Mueller YM;Yang G;Boesteanu AC;Gracias DT;Do DH;Hope JL;Kathuria N;McGettigan SE;Lewis MG;Giavedoni LD;Jacobson JM;Katsikis PD
通讯作者: Katsikis PD
DOI: 10.1038/nature20583
发表时间: 2016-12-08
期刊: NATURE
影响因子: 64.8
作者:
Borducchi, Erica N.;Cabral, Crystal;Stephenson, Kathryn E.;Liu, Jinyan;Abbink, Peter;Ng'ang'a, David;Nkolola, Joseph P.;Brinkman, Amanda L.;Peter, Lauren;Lee, Benjamin C.;Jimenez, Jessica;Jetton, David;Mondesir, Jade;Mojta, Shanell;Chandrashekar, Abishek;Molloy, Katherine;Alter, Galit;Gerold, Jeffrey M.;Hill, Alison L.;Lewis, Mark G.;Pau, Maria G.;Schuitemaker, Hanneke;Hesselgesser, Joseph;Geleziunas, Romas;Kim, Jerome H.;Robb, Merlin L.;Michael, Nelson L.;Barouch, Dan H.
通讯作者: Barouch, Dan H.
DOI: 10.1172/jci.insight.127717
发表时间: 2019-06-06
期刊: JCI INSIGHT
影响因子: 8
作者:
Del Prete, Gregory Q.;Alvord, W. Gregory;Lifson, Jeffrey D.
通讯作者: Lifson, Jeffrey D.
DOI: 10.1126/science.1234150
发表时间: 2013-05-10
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Jardine J;Julien JP;Menis S;Ota T;Kalyuzhniy O;McGuire A;Sok D;Huang PS;MacPherson S;Jones M;Nieusma T;Mathison J;Baker D;Ward AB;Burton DR;Stamatatos L;Nemazee D;Wilson IA;Schief WR
通讯作者: Schief WR
重新分析接受 HIV-1 潜伏期逆转剂治疗的 CD4+ T 细胞的基因表达谱。
DOI: 10.3390/microorganisms8101505
发表时间: 2020-09-30
期刊: Microorganisms
影响因子: 4.5
作者:
Campos Coelho AV;Moura RR;Crovella S
通讯作者: Crovella S